Results 21 to 30 of about 114,683,953 (299)
Botulinum toxin a in the treatment of blepharospasm - A 10-year experience [PDF]
, 2005 To evaluate the long-term effect of botulinum toxin type A (BTX) in the treatment of blepharospasm, a retrospective analysis was conducted from the patients seen at the Movement Disorders Clinic of the Department of Neurology, Hospital das Clinicas ...
Goncalves, LR +7 more
core +1 more source
Botulinum Toxin as Preventive Treatment for Migraine: A Randomized Double-Blind Study [PDF]
, 2009 Aim: To determine if botulinum toxin type A (BoNT-A) injections can reduce the frequency and severity of migraines. Methods: Patients (n = 127) were randomized to receive placebo or two doses of BoNT-A (Dysport (R)). The primary endpoint was reduction in
Toelle, Thomas +13 more
core +1 more source
Botulinum Toxin Injection for the Treatment of Upper Esophageal Sphincter Dysfunction
Toxins, 2022 Dysphagia associated with upper esophageal sphincter (UES) dysfunction remarkably affects the quality of life of patients. UES injection of botulinum toxin is an effective treatment for dysphagia. In comparison with skeletal muscles of the limb and trunk,
Pengxu Wei
doaj +1 more source
The light chain but not the heavy chain of botulinum A toxin inhibits exocytosis from permeabilized adrenal chromaffin cells [PDF]
, 1989 The heavy and light chains of botulinum A toxin were separated by anion exchange chromatography. Their intracellular actions were studied using bovine adrenal chromaffin cells permeabilized with streptolysin O.
M. Gratzl +10 more
core +1 more source
Botulinum Toxin A for the Treatment of Keloids [PDF]
, 2012 Introduction: Keloids are the result of excessive scar tissue formation. Besides their poor aesthetic appearance, keloids can be associated with severe clinical symptoms such as pain, itching, and rigidity.
Bureik, D. +11 more
core +1 more source
PLoS ONE, 2014 Botulinum neurotoxin (BoNT) is the most poisonous substances known and its eight toxin types (A to H) are distinguished by the inability of polyclonal antibodies that neutralize one toxin type to neutralize any of the other seven toxin types.
Nir Dover +5 more
doaj +1 more source
Intra-sphincteric botulinum toxin in the management of functional biliary pain
Endoscopy International Open, 2022 Background and study aims The management of functional biliary-type pain remains a clinical challenge. Intra sphincteric botulinum toxin putatively exerts an anti-spasmodic and anti-nociceptive effect.
Shyam Menon, Andrew Holt, Adam D. Farmer
doaj +1 more source
Tremor and Other Hyperkinetic Movements, 2012 Background: It is generally agreed that diffusion of botulinum toxin occurs, but the extent of the spread and its clinical importance are disputed. Many factors have been suggested to play a role but which have the most clinical relevance is a subject of much discussion.
Brodsky, Matthew A. +2 more
openaire +5 more sources
Botulinum toxin A for the Treatment of Overactive Bladder
Toxins, 2016 The standard treatment for overactive bladder starts with patient education and behavior therapies, followed by antimuscarinic agents. For patients with urgency urinary incontinence refractory to antimuscarinic therapy, currently both American Urological
Po-Fan Hsieh +4 more
doaj +1 more source
Journal of Rehabilitation Medicine, 2020 Objective: To evaluate the role of diagnostic nerve block in predicting the outcome of subsequent botulinum toxin type A treatment for spastic equinovarus foot due to chronic stroke. Design: Retrospective observational study.
Alessandro Picelli +6 more
doaj +1 more source